Eosinophilic Esophagitis Eoe clinical trials

Explore recruiting eosinophilic esophagitis eoe clinical trials.

Recruiting eosinophilic esophagitis eoe studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Eosinophilic Esophagitis Eoe trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

"A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS"

Italy, Germany, Austria, Portugal, Belgium, Spain +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1b/2 Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of EP 104GI in Adults with Eosinophilic Esophagitis (RESOLVE)

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ANB033

Netherlands, Finland, Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Double-blind, double-dummy, randomized, parallel-group, non-inferiority phase III trial on the efficacy and tolerability of 2 mg once daily vs. 1 mg twice daily budesonide orodispersible tablets for induction of histological remission in adults with eosinophilic esophagitis

Germany, Portugal, Austria, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING)

Greece, Belgium, Denmark, Germany, Spain, Austria +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Eosinophilic Esophagitis Eoe trials by city

Eosinophilic Esophagitis Eoe in Toronto Eosinophilic Esophagitis Eoe in Vancouver Eosinophilic Esophagitis Eoe in Montreal Eosinophilic Esophagitis Eoe in Calgary Eosinophilic Esophagitis Eoe in Edmonton Eosinophilic Esophagitis Eoe in Ottawa Eosinophilic Esophagitis Eoe in Winnipeg Eosinophilic Esophagitis Eoe in Quebec City Eosinophilic Esophagitis Eoe in Hamilton Eosinophilic Esophagitis Eoe in Kitchener Eosinophilic Esophagitis Eoe in London Eosinophilic Esophagitis Eoe in Halifax Eosinophilic Esophagitis Eoe in New York Eosinophilic Esophagitis Eoe in Los Angeles Eosinophilic Esophagitis Eoe in Chicago Eosinophilic Esophagitis Eoe in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease